Endothelin and endothelin antagonists in hypertension

Journal of Hypertension

Volumn 16, Issue 12 SUPPL., 1998, Pages 1891-1895

  Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Blood vessels; Endothelium; Essential hypertension; Experimental hypertension; Resistance arteries; Salt sensitive hypertension; Vascular growth

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ANGIOTENSIN; ATRASENTAN; BOSENTAN; BQ 610; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DEOXYCORTICOSTERONE ACETATE; ENALAPRIL; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; FRUCTOSE; HORMONE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; NITRIC OXIDE; PROSTACYCLIN; RES 701 1; SODIUM; TAK 044; VASOCONSTRICTOR AGENT;

ARTERY; BLOOD PRESSURE REGULATION; BLOOD VESSEL; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; ENDOTHELIUM; FOREARM BLOOD FLOW; HEART FAILURE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENOVASCULAR HYPERTENSION; SMOOTH MUSCLE; SMOOTH MUSCLE CONTRACTION; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; VASODILATATION;

EID: 0032435964     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816121-00007     Document Type: Conference Paper

References (69)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
2. Inoue A. Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T. The human endothelin family - 3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc Natl Acad Sci USA 1989; 86:2863-2867.
3. Arai H, Hori S, Aramori I, Ohkuba H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732
4. Sakurai T, Yanagisawa M, Takuwa H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
5. De Nucci G, Thomas R. D'Orléans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797-9800.
6. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy [brief review]. Hypertension 1995, 25:1135-1143.
7. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368:703-710.
8. Russell FD, Skepper JN, Davenport AP. Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J Cardiovasc Pharmacol 1997; 29:820-826.
9. Yamazaki T, Komuro I, Kudoh S, Zou S, Shiojima I, Hiroi Y. et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996; 271:3221-3228.
10. Ito H, Adachi S, Tamamori M, Fujisaki H, Tanaka M, Lin M, et al. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes:a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996; 28:1271-1277.
11. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes, J Clin Invest 1993; 92:398-403.
12. 2+ modulation. Circ Res 1996; 78:302-311.
13. Shubeita HE, Mcdonough PM, Harris AN, Knowlton KU, Glembotski CC, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265:20555-20562.
14. Clavell AL, Stingo AJ, Margulies KB, Brandt RR, Burnett JC Jr, Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol Renal, Fluid Electrolyte Physiol 1995; 268:F455-F460.
15. Wilkins FC Jr, Alberola A, Mizelle HL, Opgenorth TJ, Granger JP. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol Regul Integr Comp Physiol 1995; 268:R375-R381.
16. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998; 19:5-8.
17. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
18. Larivière R. Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21:916-920.
19. Li J-S, Larivière R. Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-188.
20. Schiffrin EL, Larivière R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25 (part 2):769-773.
21. Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol 1996; 27:643-651.
22. Day R, Larivière R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 1995; 8:294-300.
23. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115:1377-1381.
24. Li JS, Schürch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996; 9:803-811.
25. D'Uscio LV, Barton M, Shaw S, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension - effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997; 30:905-911
26. Larivière R, Sventek P, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive rats. Life Sci 1995; 56:1889-1896.
27. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995; 25 (part 1):495-500.
28. Li JS, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 1995; 13:647-652.
29. Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol 1996; 7:1158-1164.
30. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997; 30:29-34.
31. A-receptor antagonist. Circulation 1997; 96:1593-1597.
32. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 1996; 14:57-64.
33. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol (Heart Circ Physiol) 1996; 40:H88-H93.
34. Verma S, Bhanot S, McNeill JH. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995; 269 (6 part 2):H2017-H2021.
35. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78:225-228.
36. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol (Cell Physiol) 1990; 258:C408-C415.
37. Schiffrin EL, Larivière R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 1996; 33:235-248.
38. Lariviëre R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol 1995; 27:2123-2131.
39. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension 1995; 25:449-452.
40. Sventek P, Turgeon A, Schiffrin EL. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation 1997; 95:240-244.
41. Deng LY, Schiffrin EL. Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertensive rats. J Cardiovasc Pharmacol 1998; 31 (suppl 1):S380-S383.
42. Schiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol 1997; 12:354-367.
43. Karam H, Heudes D, Bruneval P, Gonzales MF, Löffler BM, Clozel M, Clozel JP. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats - comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996; 28:379-385.
44. B receptor antagonist. Circulation 1996; 93:2068-2079.
45. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355.
46. Kato T, Kassab S, Wilkins FC Jr, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 1995; 25:883-887.
47. Bird JE, Webb ML, Giancarli MR, Chao CC, Dorso CR, Asaad MM. A role for endothelin ETA receptors in regulation of renal function in spontaneously hypertensive rats. Eur J Pharmacol 1995; 294:183-189.
48. A-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 1998; 31:995-1001.
49. Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997; 30:1578-1584.
50. Kassab S, Novak J, Miller T, Kirchner K, Granger J. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension. Hypertension 1997; 30:682-686.
51. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-444.
52. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP. Nonpeptide endothelin receptor antagonists. 5. Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995; 275:200-206.
53. Benigni A, Zoja C, Corna D, Orisio S, Facchinetti D, Benatti L, Remuzzi G. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996; 27:416-423.
54. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C. et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma. Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 1990; 78:261-264.
55. Kohno M, Yasumari K, Murakawa K, Yokokawa K, Horio T, Fukui T, Takeda T. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
56. Schiffrin EL, Thibault G:Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
57. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28:652-655.
58. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93:1860-1870.
59. Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996; 93:866-869.
60. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in endothelium of resistance arteries in severe human essential hypertension. J Hypertens 1997; 15:57-63.
61. Takahashi K, Totsune K, Mouri T. Endothelin in chronic renal failure. Nephron 1994; 66:373-379.
62. Carlini R, Obialo Cl, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 1993; 6:103-107.
63. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 1996; 27:1341-1345.
64. Oishi S, Sasaki M, Sato T. Elevated immunoreactive endothelin levels in patients with pheochromocytoma. Am J Hypertens 1994; 7:717-722.
65. Wang M-X, Brown MA, Buddle ML, Carlton MA, Cario GM, Whitworth JA. Endothelin excretion in hypertensive pregnancy: relationship to glomerular filtration rate, blood pressure, and sodium excretion. Am J Hypertens 1994; 7:308-313.
66. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancer 1995; 346:732-736.
67. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V, Bosentan Hypertension Investigators: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338:784-790.
68. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16:1081-1098.
69. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.